MétaCan
Menu
Back to cohort
Record W3002933537 · doi:10.1016/j.bbmt.2019.12.469

Myeloma Patients Relapsing after First Line Treatment with Tandem Auto/Allo Transplant or Auto Transplant Only Have Similar Outcomes.

2020· article· en· W3002933537 on OpenAlexaff
Jean‐Sébastien Claveau, Richard LeBlanc, Imran Ahmad, Séverine Landais, Nadia M. Bambace, Léa Bernard, Sandra Cohen, Jean‐Sébastien Delisle, Thomas Kiss, Silvy Lachance, Denis‐Claude Roy, Guy Sauvageau, Jean Roy

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2020
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsUniversité de MontréalHôpital Maisonneuve-Rosemont
Fundersnot available
KeywordsMedicineFludarabineMelphalanMultiple myelomaInternal medicineHematopoietic stem cell transplantationCyclophosphamideCohortTransplantationLenalidomideSurgeryGastroenterologyOncologyChemotherapy

Abstract

fetched live from OpenAlex

Background A better survival in patients with multiple myeloma (MM) progressing after tandem autologous (auto)/allogeneic (allo) hematopoietic stem cell transplantation (HSCT) has been previously reported (Htut M. et al. BBMT 2018), suggesting a persistent graft-versus-multiple myeloma (GvMM) effect even after relapse. We sought to confirm this observation in a homogeneous cohort of MM patients who relapsed after upfront tandem auto/allo HSCT in our institution. Methods 92 consecutive, newly diagnosed MM patients who received tandem auto/allo HSCT were paired with 81 patients who received auto HSCT only between 2001 and 2010. Patients pairing criteria were age ≤ 65 years at diagnosis, Durie-Salmon 1B, 2 or 3, a glomerular filtration rate ≥ 60 mL/min, only one line of induction treatment, absence of progression within 4 months of auto HSCT and cytogenetics (if available). After their 1 st auto HSCT with high dose melphalan, all allo transplant recipients received an outpatient nonmyeloablative conditioning of fludarabine 30 mg/m 2 and cyclophosphamide 300 mg/m 2 × 5 days followed by G-CSF mobilized stem cells from a matched sibling donor. Results Median age in the auto/allo group was 53 years, compared to 57 years in the auto group (p<0.001). Both groups were similar for sex, immunoglobulin isotype, Durie-Salmon and ISS stages. With a median follow-up of 13.1 and 10.2 years (p<0.001), respectively, median overall survival (OS) in the tandem group has not been reached, compared to 6.1 years in the auto group only (p<0.001, Fig. 1). OS and PFS at 10 years in tandem and auto groups were 61% vs 37% (p<0.001) and 49% vs 22% (p<0.001), respectively. Disease progression occurred in 46 of 92 tandem recipients and 63 of 81 auto recipients, with an estimated 10-year cumulative incidence of progression (CIP) significantly lower in the tandem group (50% vs 77%; p<0.001, Fig. 2). Median OS at 10 years after 1 st progression was 39% in the tandem group and 22% in the auto group (p=0.062, Fig. 3). In multivariate analysis of factors associated with CIP, the only significant variable was tandem transplant (hazard ratio 0.44; 95% CI: 0.24-0.80, p=0.008), independently from age, ISS stage, type of induction and response before 1 st auto HSCT. Main cause of death was MM in both groups. Conclusion Tandem auto/allotransplant enables long-term survival and offers a potentially curative option in selected newly diagnosed MM patients. At time of 1 st relapse, tandem auto/allo transplant does not confer a significant outcome advantage compared to auto HSCT only.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.267
Teacher spread0.244 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207